A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis
Abstract Background The prognosis of patients with recurrences from stage 4 neuroblastoma is not uniformly dismal. The evaluation of new therapies therefore needs to consider the individual risks of the treated patients. This study aims to define clinically useful risk criteria. Patients and Methods...
Main Authors: | Kiana Kreitz, Angela Ernst, René Schmidt, Thorsten Simon, Matthias Fischer, Ruth Volland, Barbara Hero, Frank Berthold |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2562 |
Similar Items
-
Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months
by: Janina Fischer, et al.
Published: (2017-08-01) -
Novel Therapies for Relapsed and Refractory Neuroblastoma
by: Peter E. Zage
Published: (2018-10-01) -
Neuroblastoma in an adult: a case report of a rare entity with a summary review
by: Fadoua Rais, et al.
Published: (2017-03-01) -
The Evolution of Risk Classification for Neuroblastoma
by: Elizabeth Sokol, et al.
Published: (2019-02-01) -
High-Risk Neuroblastoma Treatment Review
by: Valeria Smith, et al.
Published: (2018-08-01)